ELISA/assay

Human c myc Oncogene product ELISA Kit

MBS724210

48-Strip-Wells-(Comp

470 USD

ELISA Kit

Human c myc Oncogene product ELISA Kit

c myc Oncogene product

c-myc, partial; C-myc protein; myc proto-oncogene protein; proto-oncogene c-Myc; transcription factor p64; class E basic helix-loop-helix protein 39; avian myelocytomatosis viral oncogene homolog; v-myc myelocytomatosis viral oncogene homolog; myc-related translation/localization regulatory factor; v-myc avian myelocytomatosis viral oncogene homolog; C-myc protein

C MYC

MYC; c-myc; MRTL; MYCC; c-Myc; bHLHe39

Q6LBK7_HUMAN

Human

Store all reagents at 2-8 degree C.

Assay Type: Competitive or Sandwich. Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Sensitivity: 1.0 pg/mL.

Intended Uses: This CGRP ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human CGRP. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Cancer

Principle of the Assay: CGRP ELISA kit applies the quantitative sandwich enzyme immunoassay technique. The microtiter plate has been pre-coated with a monoclonal antibody specific for CGRP. Standards or samples are then added to the microtiter plate wells and CGRP if present, will bind to the antibody pre-coated wells. In order to quantitatively determine the amount of CGRP present in the sample, a standardized preparation of horseradish peroxidase (HRP) -conjugated polyclonal antibody, specific for CGRP are added to each well to "sandwich" the CGRP immobilized on the plate. The microtiter plate undergoes incubation, and then the wells are thoroughly washed to remove all unbound components. Next, substrate solutions are added to each well. The enzyme (HRP) and substrate are allowed to react over a short incubation period. Only those wells that contain CGRP and enzyme-conjugated antibody will exhibit a change in color. The enzyme-substrate reaction is terminated by addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The CGRP concentration in each sample is interpolated from this standard curve.

396512

CAA46984.1

Q6LBK7

7,012 Da

Acute Myeloid Leukemia Pathway (83117); Acute Myeloid Leukemia Pathway (529); Apoptosis Pathway (198797); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); C-MYB Transcription Factor Network Pathway (138073); C-MYC Pathway (169344); CD40/CD40L Signaling Pathway (138061); Cell Cycle Pathway (530733); Cell Cycle, Mitotic Pathway (105765)

The protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. There is evidence to show that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini. The synthesis of non-AUG initiated protein is suppressed in Burkitt's lymphomas, suggesting its importance in the normal function of this gene. [provided by RefSeq, Jul 2008]

Myc: a proto-oncogenic transcription factor that plays a role in cell proliferation, apoptosis and in the development of human tumors. Seems to activate the transcription of growth-related genes. Protein type: Oncoprotein; DNA-binding; Transcription factor; Nucleolus. Chromosomal Location of Human Ortholog: 8q24.21. Cellular Component: nucleoplasm; protein complex; nucleolus; nucleus; cytosol. Molecular Function: protein dimerization activity; protein binding; DNA binding; protein complex binding; transcription factor binding; transcription factor activity. Biological Process: cellular iron ion homeostasis; oxygen transport; positive regulation of transcription, DNA-dependent; positive regulation of caspase activity; Wnt receptor signaling pathway through beta-catenin; negative regulation of transcription from RNA polymerase II promoter; chromosome organization and biogenesis; positive regulation of fibroblast proliferation; transforming growth factor beta receptor signaling pathway; positive regulation of mesenchymal cell proliferation; positive regulation of cell proliferation; response to gamma radiation; cell cycle arrest; response to drug; transcription initiation from RNA polymerase II promoter; Notch signaling pathway; regulation of telomere maintenance; transcription, DNA-dependent; MAPKKK cascade; negative regulation of cell division; negative regulation of stress-activated MAPK cascade; negative regulation of monocyte differentiation; chromatin remodeling; ureteric bud branching; regulation of gene expression; negative regulation of fibroblast proliferation; energy reserve metabolic process; gene expression; positive regulation of transcription from RNA polymerase II promoter; response to DNA damage stimulus; positive regulation of epithelial cell proliferation; negative regulation of apoptosis. Disease: Burkitt Lymphoma

48-Strip-Wells-(Competitive)

470 USD

48-Strip-Wells-(Sandwich)

470

96-Strip-Wells-(Competitive)

675

96-Strip-Wells-(Sandwich)

675